Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended June 30, 2026 and the Six Months Ended June 30, 2026" Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.
Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended June 30, 2026 and the Six Months Ended June 30, 2026" Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.
The financial report presents the financial statements of the company for the quarter ended June 30, 2026, as well as the year-to-date period from January 1, 2026, to June 30, 2026. The company reported total revenues of $X million and net income of $Y million for the quarter, compared to $Z million and $W million, respectively, for the same period in the prior year. The company’s balance sheet as of June 30, 2026, shows total assets of $X million, total liabilities of $Y million, and total stockholders’ equity of $Z million. The company’s cash and cash equivalents as of June 30, 2026, were $X million, and its accounts receivable and payable were $Y million and $Z million, respectively. The company’s financial performance was impacted by various factors, including changes in market conditions, competition, and the global pandemic.
Overview
Evofem is a commercial-stage biopharmaceutical company focused on women’s health. The company currently commercializes two FDA-approved products: PHEXX, a non-hormonal prescription contraceptive gel, and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis.
PHEXX as a Contraceptive; Commercial Strategies
Evofem launched PHEXX in the U.S. in September 2020 and has seen net sales growth each year since. The company’s commercial strategy includes marketing and awareness campaigns targeting healthcare providers and women, payer outreach, and consumer digital and media initiatives. Key growth drivers for 2026 include social media campaigns, participation in medical conferences, and expanding PHEXX use in women taking oral contraceptives with certain weight loss medications.
Evofem has secured coverage for PHEXX with most insurers, including Medicaid, and has achieved high approval rates. The company continues to work on increasing lives covered and gaining preferred formulary positions.
SOLOSEC
In July 2024, Evofem acquired global rights to SOLOSEC, a single-dose oral treatment for bacterial vaginosis and trichomoniasis. The company re-launched the brand in November 2024, leveraging its existing commercial infrastructure and physician relationships.
Bacterial Vaginosis
Bacterial vaginosis (BV) affects an estimated 21 million women in the U.S. If left untreated, BV can increase the risk of sexually transmitted infections and other complications. An investigator-led study found that once-weekly dosing of SOLOSEC demonstrated promising results for treating recurrent BV.
Trichomoniasis
Trichomoniasis is the most common non-viral sexually transmitted infection in the world. In clinical trials, a single dose of SOLOSEC demonstrated high cure rates for trichomoniasis in both women and men. An ongoing NIH-funded study is evaluating the efficacy and cost-effectiveness of SOLOSEC versus metronidazole for trichomoniasis treatment.
Financial Operations Overview
Evofem’s revenue is based on unit shipments to customers, including wholesalers, pharmacies, and its licensee in the UAE. Cost of goods sold includes inventory costs and royalties owed on SOLOSEC sales.
The company’s operating expenses consist of:
- Research and development: Focused on product improvements and manufacturing optimization
- Selling and marketing: Commercialization costs for PHEXX and SOLOSEC
- General and administrative: Salaries, business development, and other corporate expenses
Other income/expense includes interest, changes in fair value of financial instruments, and gains/losses on debt extinguishment.
Results of Operations
For the three and six months ended June 30, 2026, Evofem saw decreases in net product sales and cost of goods sold compared to the prior year periods, primarily due to lower PHEXX unit sales. Research and development, selling and marketing, and general and administrative expenses remained relatively flat.
The company reported significant other expenses, including losses related to changes in fair value of financial instruments and debt extinguishment.
Liquidity and Capital Resources
As of June 30, 2026, Evofem had a working capital deficit of $82.5 million and an accumulated deficit of $914.0 million. The company has financed operations primarily through equity and debt financings.
Management believes the company’s current cash and cash equivalents are insufficient to fund operations for the next 12 months. Evofem is exploring options to generate additional revenue, restructure payables, and obtain further financing through equity, debt, or partnerships. The company’s ability to continue as a going concern is uncertain.